Autres langues Tenaya Therapeutics, Inc.

Actions

TNYA

US87990A1060

Temps réel estimé Cboe BZX Autres places de cotation 19:49:51 26/04/2024			Varia. 5j.	Varia. 1 janv.
4,32 ^USD	+2,37 %		+0,93 %	+34,57 %

21/03	TENAYA THERAPEUTICS, INC. : Canaccord Genuity persiste à l'achat	ZM
18/03	Tenaya Therapeutics, Inc. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

North American Morning Briefing : Stock Futures -2-	19/03
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	18/03
Tenaya Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	18/03
Tenaya Therapeutics, Inc. Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	18/03
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences	27/02
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	26/02
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	26/02
Tenaya Therapeutics Insider Bought Shares Worth $9,999,999, According to a Recent SEC Filing	14/02
Tenaya Therapeutics Announces Pricing of Underwritten Offering	08/02
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference	21/11
Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	08/11
Tenaya Therapeutics Gets FDA Clearance For TN-401 Gene Therapy Trial	26/10/23
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	26/10/23
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	26/10/23
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting	09/10/23
Tenaya Therapeutics, Inc. Releases New Data for Tn-301 At the 2023 Heart Failure Society of America	09/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tenaya Therapeutics, Inc.

Actions

TNYA

US87990A1060

Autres langues

Filtres